Cargando…
Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML
The FLT3-ITD mutation is one of the most prevalent oncogenic mutations in AML. Several FLT3 kinase inhibitors have shown impressive activity in clinical evaluation, however clinical responses are usually transient and clinical effects are rapidly lost due to drug resistance. One of the resistance me...
Autores principales: | Wang, Aoli, Wu, Hong, Chen, Cheng, Hu, Chen, Qi, Ziping, Wang, Wenchao, Yu, Kailin, Liu, Xiaochuan, Zou, Fengming, Zhao, Zheng, Wu, Jiaxin, Liu, Juan, Liu, Feiyang, Wang, Li, Stone, Richard M., Galinksy, Ilene A., Griffin, James D., Zhang, Shanchun, Weisberg, Ellen L., Liu, Jing, Liu, Qingsong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045383/ https://www.ncbi.nlm.nih.gov/pubmed/27074558 http://dx.doi.org/10.18632/oncotarget.8675 |
Ejemplares similares
-
Selectively targeting FLT3-ITD mutants over FLT3- wt by a novel inhibitor for acute myeloid leukemia
por: Wang, Aoli, et al.
Publicado: (2020) -
getITD for FLT3-ITD-based MRD monitoring in AML
por: Blätte, Tamara J., et al.
Publicado: (2019) -
Targeting chaperon protein HSP70 as a novel therapeutic strategy for FLT3-ITD-positive acute myeloid leukemia
por: Hu, Chen, et al.
Publicado: (2021) -
Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD(+) AML cell growth
por: Weir, Mark C., et al.
Publicado: (2017) -
FLT3-ITD allelic ratio and HLF expression predict FLT3 inhibitor efficacy in adult AML
por: Kivioja, Jarno, et al.
Publicado: (2021)